They could be. Integrilin would seem to be a good candidate for MNTA’s technology insofar as it’s hard to copy (and hence attractive to MNTA from a competitive standpoint) while also being regulated by the FDA as a small-molecule drug, which allows a generic to be fully substitutable for the branded product. The Integrilin patents in the Orange Book expire in 2014-2015.
Market Data 
Markets 
AI
